SCHEMBL4873250

SCHEMBL4873250

[c]1cc(-c2cc3ccccc3cn2)nc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.42
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
BTK Q06187 1/20 0.39
NQO2 P16083 1/20 0.38
GPR3 P46089 1/20 0.38
CYP2A6 P11509 1/20 0.38
PDPK1 O15530 1/20 0.38
MIF P14174 1/20 0.37
GRM4 Q14833 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ACHE P22303 1/20 0.35
TERT O14746 1/20 0.33
NPY5R Q15761 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875167 0.82 MAPT (0.46) NPC1RAB9AKDM4ETDP1NQO2
SCHEMBL5470573 0.76 NPC1 (0.63) NPC1RAB9AKDM4ECYP1A2TDP1
SCHEMBL547311 0.76 PDGFRB (0.49) CYP1A2CYP2A6GRM4ALDH1A1GLA
SCHEMBL4875157 0.76 RAB9A (0.46) NPC1RAB9AKDM4ECYP1A2TDP1
SCHEMBL8102371 0.75 KDM4E (0.50) NPC1RAB9AKDM4ECYP1A2TDP1
SCHEMBL8094325 0.74 METAP2 (0.45) NPC1RAB9AKDM4ECYP2A6L3MBTL1
SCHEMBL20873053 0.74 NPC1 (0.49) NPC1RAB9AKDM4ECYP1A2TDP1
SCHEMBL8090146 0.73 ALDH1A1 (0.38) NPC1RAB9AKDM4ECYP1A2TDP1
SCHEMBL234452 0.72 ACHE (0.47) RAB9AKDM4ETDP1NQO2ALDH1A1
SCHEMBL4878663 0.71 NPC1 (0.36) NPC1RAB9AKDM4ECYP1A2GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080015193-A1 Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof AGRIUS GROUP, LLC. 2008-01-17 US claimed
WO-2007149395-A2 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AMPHORA DISCOVERY CORPORATION (US) 2007-12-27 WO claimed
US-20080015193-A1 Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof AGRIUS GROUP, LLC. 2008-01-17 US disclosed
WO-2007149395-A2 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AMPHORA DISCOVERY CORPORATION (US) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015193-A1 Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK NPC1 2981/4885RAB9A 3960/4885KDM4E 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.